Age-Related Variations of Muscle Mass, Strength, and Physical Performance in Community-Dwellers: Results From the Milan EXPO Survey

2017 ◽  
Vol 18 (1) ◽  
pp. 88.e17-88.e24 ◽  
Author(s):  
Francesco Landi ◽  
Riccardo Calvani ◽  
Matteo Tosato ◽  
Anna Maria Martone ◽  
Domenico Fusco ◽  
...  
Keyword(s):  
Muscle Mass ◽  
Physical Performance ◽  
Age Related ◽  
Community Dwellers

scholarly journals The Relationship Between Intermuscular Fat and Physical Performance Is Moderated by Muscle Area in Older Adults

2020 ◽  
Vol 76 (1) ◽  
pp. 115-122
Author(s):  
Samaneh Farsijani ◽  
Adam J Santanasto ◽  
Iva Miljkovic ◽  
Robert M Boudreau ◽  
Bret H Goodpaster ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Muscle Mass ◽  
Physical Performance ◽  
Functional Limitations ◽  
Negative Association ◽  
Muscle Area ◽  
Cross Sectional ◽  
Age Related ◽  
Intermuscular Fat ◽  
The Mean

Abstract Background Age-related deposition of fat in skeletal muscle is associated with functional limitations. Skeletal muscle fat may be present in people with preserved muscle mass or accompanied by muscle wasting. However, it is not clear if the association between muscle fat deposition and physical performance is moderated by muscle mass. Objective To determine whether the association between midthigh intermuscular fat and physical performance is moderated by muscle area. Methods We performed a cross-sectional analysis of the Health, Aging, and, Body Composition (ABC) study data collected in 2002–2003 (n = 1897, women: 52.2%). Midthigh muscle cross-sectional area (by computed tomography) and physical performance measures were compared across quartiles of intermuscular fat absolute area. Moderation analysis was performed to determine the conditional effect of intermuscular fat on physical performance as a function of muscle area. Conditional effects were evaluated at three levels of muscle area (mean and ± 1 standard deviation [SD]; 213.2 ± 53.2 cm2). Results Simple slope analysis showed that the negative association between intermuscular fat area (cm2) and leg strength (N·m) was of greater magnitude (beta coefficient [b], 95% confidence interval [CI] = −0.288 [−0.427, −0.148]) in participants with greater muscle area (ie, 1 SD above the mean) compared to those with lower muscle area (ie, at mean [b = −0.12 {−0.248, 0.008}] or 1 SD below the mean [b = 0.048 {−0.122, 0.217}]). Similarly, the negative association of intermuscular fat with 400-m walk speed (m/s) and chair stand (seconds) was greater in those with higher muscle areas (p < .001) compared to those with lower muscle areas. Conclusions The association between higher intermuscular fat area and impaired physical function in aging is moderated by muscle area.

scholarly journals Sarcopenia in chronic kidney disease – A brief review

2021 ◽  
Vol 35 (2) ◽  
Author(s):  
Beatriz Donato ◽  
◽  
Catarina Teixeira ◽  
Sónia Velho ◽  
Edgar Almeida ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Muscle Mass ◽  
Physical Performance ◽  
Functional Independence ◽  
Muscle Dysfunction ◽  
Skeletal Muscle Dysfunction ◽  
Age Related ◽  
The Impact

Sarcopenia is a progressive age -related loss of muscle mass associated with a decline in muscle function and physical performance. Patients with chronic kidney disease experience substantial loss of muscle mass, weakness, and poor physical performance. Indeed, with the progression of chronic kidney disease, skeletal muscle dysfunction contributes to mobility limitation, loss of functional independence, and vulnerability to disease complications. There is a lack of robust data on the negative effect of the impact of kidney disease on skeletal muscle dysfunction, as well as on screening and treatment strategies that can be used in clinical practice to prevent functional decline and disability. Therefore, sarcopenia may be an underestimated condition with major implications for people with chronic kidney disease, even before the start of dialysis, which makes research into this topic necessary. The purpose of this review is to expand on some fundamental topics of sarcopenia, with an emphasis on the setting of chronic kidney disease patients.

scholarly journals Gut Microbiota, Muscle Mass and Function in Aging: A Focus on Physical Frailty and Sarcopenia

Nutrients ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 1633 ◽  
Author(s):  
Andrea Ticinesi ◽  
Antonio Nouvenne ◽  
Nicoletta Cerundolo ◽  
Pamela Catania ◽  
Beatrice Prati ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Physical Function ◽  
Muscle Mass ◽  
Physical Performance ◽  
Microbiota Composition ◽  
Physical Frailty ◽  
Deficit Accumulation ◽  
Cross Sectional ◽  
Age Related ◽  
And Function

Human gut microbiota is able to influence the host physiology by regulating multiple processes, including nutrient absorption, inflammation, oxidative stress, immune function, and anabolic balance. Aging is associated with reduced microbiota biodiversity, increased inter-individual variability, and over-representation of pathobionts, and these phenomena may have great relevance for skeletal muscle mass and function. For this reason, the presence of a gut-muscle axis regulating the onset and progression of age-related physical frailty and sarcopenia has been recently hypothesized. In this narrative review, we summarize the studies supporting a possible association between gut microbiota-related parameters with measures of muscle mass, muscle function, and physical performance in animal models and humans. Reduced muscle mass has been associated with distinct microbiota composition and reduced fermentative capacity in mice, and the administration of probiotics or butyrate to mouse models of muscle wasting has been associated with improved muscle mass. However, no studies have targeted the human microbiome associated with sarcopenia. Limited evidence from human studies shows an association between microbiota composition, involving key taxa such as Faecalibacterium and Bifidobacterium, and grip strength. Similarly, few studies conducted on patients with parkinsonism showed a trend towards a different microbiota composition in those with reduced gait speed. No studies have assessed the association of fecal microbiota with other measures of physical performance. However, several studies, mainly with a cross-sectional design, suggest an association between microbiota composition and frailty, mostly assessed according to the deficit accumulation model. Namely, frailty was associated with reduced microbiota biodiversity, and lower representation of butyrate-producing bacteria. Therefore, we conclude that the causal link between microbiota and physical fitness is still uncertain due to the lack of targeted studies and the influence of a large number of covariates, including diet, exercise, multimorbidity, and polypharmacy, on both microbiota composition and physical function in older age. However, the relationship between gut microbiota and physical function remains a very promising area of research for the future.

scholarly journals Sarcopenia – 2021

2021 ◽  
Vol 162 (1) ◽  
pp. 3-12
Author(s):  
Alajos Pár ◽  
Jenő Péter Hegyi ◽  
Szilárd Váncsa ◽  
Gabriella Pár
Keyword(s):  
Skeletal Muscle ◽  
Muscle Strength ◽  
Muscle Mass ◽  
Physical Performance ◽  
Adverse Outcomes ◽  
Muscle Disease ◽  
Low Grade ◽  
Related Disorder ◽  
Alcoholic Fatty Liver ◽  
Age Related

Összefoglaló. A sarcopenia progresszív, generalizált vázizombetegség az izomtömeg fogyásával és az izomfunkció romlásával, számos szövődménnyel, rossz prognózissal. A sarcopeniát eredetileg életkorfüggő, idősekben jelentkező kórképnek írták le (primaer sarcopenia). Később derült ki, hogy fiatal- és középkorú személyeknél is előfordul, különböző betegségekhez társulva (secundaer sarcopenia). A közlemény áttekintést ad a betegség patofiziológiájáról, a fizikai inaktivitás, az inzulinrezisztencia, a krónikus gyulladás, a citokinek, hepatokinek és miokinek szerepéről az izomkárosodásban, valamint az izom, a zsírszövet és a máj funkcionális kapcsolatairól nem alkoholos zsírmájban és cirrhosisban. A diagnózis felállítását számos funkcionális próba, illetve vizsgálóeljárás teszi lehetővé. Az izomerő-csökkenés igazolása a legfontosabb paraméter (kézszorító erő). Az izomtömegvesztést kettős energiájú röntgenabszorpciometria, bioelektromosimpedancia-analízis, komputertomográfia vagy mágneses rezonanciás képalkotó vizsgálat mutathatja ki, megerősítve a kórismét, a fizikai teljesítmény csökkenése pedig a sarcopenia súlyosságát jelzi. A sarcopenia kezelése és a progresszió prevenciója a fiatalkorban elkezdett és élethosszig tartó rendszeres fizikai aktivitáson, a protein-kalória túltápláláson és a gyógyszeres terápián alapul, beleértve a D-vitamin és a tesztoszteron pótlását, az elágazó láncú aminosavak és az L-karnitin adását. Másodlagos sarcopeniában az alapbetegség kezelése is szükséges. Orv Hetil. 2021; 162(1): 3–12. Summary. Sarcopenia is a progressive, generalized skeletal muscle disease with the loss of muscle mass and function, associated with adverse outcomes and poor prognosis. Sarcopenia first was regarded as an age-related disorder of older people (primary sarcopenia). Later it turned out that it can also occur in young age due to a range of chronic disorders such as cancer, anorexia or malnutrition (secondary sarcopenia). This paper overviews the pathophysiology of sarcopenia and the factors involved in the muscle mass loss, i.e., physical inactivity, insulin resistance, low-grade chronic inflammation, hepatokines and myokines. The basic feature is the imbalance between proteolysis and protein synthesis that leads to muscle atrophy. We discuss the relationship between liver, muscle and adipose tissue in non-alcoholic fatty liver disease and cirrhosis. To diagnose sarcopenia, there are a range of tests and tools that measure muscle strength and muscle mass as well as physical performance. The low muscle strength (hand grip strength) is the primary parameter of the diagnosis, the best measure of muscle function. The loss of skeletal muscle mass assessed by dual-energy X-ray absorptiometry, bioelectric impedance analysis, computer tomography, or magnetic resonance imaging confirms diagnosis, while the decrease in physical performance reflects severe sarcopenia. For the treatment and prevention of progression, the most important is the regular physical activity started from early adulthood, and healthy diet containing protein-calorie hyperalimentation. In addition, a pharmacotherapy with the supplementation of vitamin D and testosterone, furthermore, the administration of L-carnitine and branched-chain amino acids can be recommended. In the case of secondary sarcopenia, the underlying disease also requires treatment. Orv Hetil. 2021; 162(1): 3–12.

Serum GDF15 Level Is Independent of Sarcopenia in Older Asian Adults

Gerontology ◽  
2021 ◽  
pp. 1-7
Author(s):  
Ha Thi Nga ◽  
Il-Young Jang ◽  
Da Ae Kim ◽  
So Jeong Park ◽  
Jin Young Lee ◽  
...  
Keyword(s):  
Grip Strength ◽  
Muscle Mass ◽  
Physical Performance ◽  
Gait Speed ◽  
Muscle Metabolism ◽  
Short Physical Performance Battery ◽  
Muscle Physiology ◽  
Skeletal Muscle Index ◽  
Age Related

Background: Growth differentiation factor 15 (GDF15), induced by tissue inflammation and mitochondrial stress, has received significant attention as a biomarker of mitochondrial dysfunction and has been implicated in various age-related diseases. However, the association between circulating GDF15 and sarcopenia-associated outcomes in older adults remains to be established. Aim: To validate previous experimental data and to investigate the possible role of GDF15 in aging and muscle physiology in humans, this study examined serum GDF15 levels in relation to sarcopenia-related parameters in a cohort of older Asian adults. Methods: Muscle mass and muscle function-related parameters, such as grip strength, gait speed, chair stands, and short physical performance battery score were evaluated by experienced nurses in 125 geriatric participants with or without sarcopenia. Sarcopenia was diagnosed using the Asian-specific cutoff points. Serum GDF15 levels were measured using an enzyme immunoassay kit. Results: Serum GDF15 levels were not significantly different according to sarcopenia status, muscle mass, muscle strength, and physical performance and were not associated with the skeletal muscle index, grip strength, gait speed, time to complete 5 chair stands, and short physical performance battery score, regardless of adjustments for sex, age, and BMI. Conclusions: These findings indicate that the definite role of GDF15 on muscle metabolism observed in animal models might not be evident in humans and that elevated GDF15 levels might not predict the risk for sarcopenia, at least in older Asian adults.

scholarly journals An update on methods for sarcopenia diagnosis: from bench to bedside

2018 ◽  
Vol 12 (2) ◽  
pp. 97 ◽  
Author(s):  
Andrea P. Rossi ◽  
Sofia Rubele ◽  
Alessia D'Introno ◽  
Elena Zoico ◽  
Piero Bradimarte ◽  
...  
Keyword(s):  
Muscle Strength ◽  
Diagnostic Criteria ◽  
Muscle Mass ◽  
Physical Performance ◽  
Adverse Outcomes ◽  
Assessment Tools ◽  
Age Related ◽  
Current Assessment

Sarcopenia has been recognized as an age-related syndrome characterized by low muscle mass, low muscle strength, and low physical performance that is associated with increased likelihood of adverse outcomes including falls, fractures, hospitalization, frailty and mortality. Therefore, it is necessary to identify the condition early for applying intervention and prevention of the disastrous consequences of sarcopenia if left untreated. Clinical definition and diagnostic criteria for sarcopenia have been developed in the last years and different tools have been proposed for screening subjects with sarcopenia, evaluating the muscle mass, the muscle strength and the physical performance. In this review we analyzed the diagnostic criteria of sarcopenia and examined the current assessment tools used for the diagnosis and screening of sarcopenia.

Age-related skeletal muscle mass loss and physical performance in Taiwan: Implications to diagnostic strategy of sarcopenia in Asia

2013 ◽  
Vol 13 (4) ◽  
pp. 964-971 ◽  
Author(s):  
Li-Kuo Liu ◽  
Wei-Ju Lee ◽  
Chien-Liang Liu ◽  
Liang-Yu Chen ◽  
Ming-Hsien Lin ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Mass Loss ◽  
Muscle Mass ◽  
Physical Performance ◽  
Skeletal Muscle Mass ◽  
Diagnostic Strategy ◽  
Age Related ◽  
Muscle Mass Loss

scholarly journals Molecular Mechanism and Pathogenesis of Sarcopenia: An Overview

2021 ◽  
Vol 22 (6) ◽  
pp. 3032
Author(s):  
Anna Picca ◽  
Riccardo Calvani
Keyword(s):  
Skeletal Muscle ◽  
Molecular Mechanism ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Strength Function ◽  
Age Related

Sarcopenia involves a progressive age‐related decline of skeletal muscle mass and strength/function [...]

scholarly journals Molecular and phenotypic analysis of rodent models reveals conserved and species-specific modulators of human sarcopenia

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Anastasiya Börsch ◽  
Daniel J. Ham ◽  
Nitish Mittal ◽  
Lionel A. Tintignac ◽  
Eugenia Migliavacca ◽  
...  
Keyword(s):  
Muscle Mass ◽  
Inflammatory Responses ◽  
Molecular Data ◽  
Model Organisms ◽  
Sequencing Data ◽  
Phenotypic Analysis ◽  
Age Related ◽  
Analogous Data ◽  
Species Specific ◽  
And Function

AbstractSarcopenia, the age-related loss of skeletal muscle mass and function, affects 5–13% of individuals aged over 60 years. While rodents are widely-used model organisms, which aspects of sarcopenia are recapitulated in different animal models is unknown. Here we generated a time series of phenotypic measurements and RNA sequencing data in mouse gastrocnemius muscle and analyzed them alongside analogous data from rats and humans. We found that rodents recapitulate mitochondrial changes observed in human sarcopenia, while inflammatory responses are conserved at pathway but not gene level. Perturbations in the extracellular matrix are shared by rats, while mice recapitulate changes in RNA processing and autophagy. We inferred transcription regulators of early and late transcriptome changes, which could be targeted therapeutically. Our study demonstrates that phenotypic measurements, such as muscle mass, are better indicators of muscle health than chronological age and should be considered when analyzing aging-related molecular data.

Sign in / Sign up

Export Citation Format

Share Document